首页 > 最新文献

Psoriasis (Auckland, N.Z.)最新文献

英文 中文
A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report. 成功治疗介形性银屑病伴银屑病关节炎的儿童一例报告。
Pub Date : 2020-12-30 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S285832
Rasmia Rowawi, Gilang Dwipangestu, Oki Suwarsa, Hartati Purbo Dharmadji, Endang Sutedja, Miranti Pangastuti, Hendra Gunawan

Psoriasis may manifest as severe hyperkeratotic lesions resembling an oyster shell called ostraceous psoriasis (OP). This type of psoriasis is extremely rare and is often associated with psoriatic arthritis (PA). Cases of OP associated with PA in children have never been reported before. We reported a 9-year-old girl with hyperkeratotic lesions resembling an oyster shell all over the body accompanied with swelling on joints of both fingers, knee joints, and ankle. Histopathological examination supported the diagnosis of OP. The diagnosis of PA was established according to the Classification Criteria for Psoriatic Arthritis (CASPAR). Significant improvements of the skin lesions and joints involved were observed within 44 days after the beginning of treatment with cyclosporine and a combination of high potent topical steroid with emollient. OP associated with PA is uncommonly seen in children. High potent corticosteroid combined with emollient showed good result in skin improvement with low side effects. In addition, cyclosporine can be a good choice of systemic therapy for OP with PA in children.

牛皮癣可能表现为严重的角化过度病变,类似牡蛎壳,称为介形性牛皮癣(OP)。这种类型的银屑病非常罕见,通常与银屑病关节炎(PA)有关。儿童OP合并PA的病例从未报道过。我们报告了一个9岁的女孩,她全身出现类似牡蛎壳的角化过度病变,并伴有手指、膝关节和脚踝关节肿胀。组织病理学检查支持op的诊断。根据银屑病关节炎分类标准(CASPAR)建立PA的诊断。在开始环孢素和高效局部类固醇与润肤剂联合治疗后44天内,观察到皮肤病变和关节的显著改善。OP合并PA在儿童中并不常见。强效皮质类固醇联合润肤剂对皮肤改善效果好,副作用小。此外,环孢素可以作为儿童OP合并PA的全身治疗的良好选择。
{"title":"A Successful Treatment of Ostraceous Psoriasis Associated with Psoriatic Arthritis in Children: A Case Report.","authors":"Rasmia Rowawi,&nbsp;Gilang Dwipangestu,&nbsp;Oki Suwarsa,&nbsp;Hartati Purbo Dharmadji,&nbsp;Endang Sutedja,&nbsp;Miranti Pangastuti,&nbsp;Hendra Gunawan","doi":"10.2147/PTT.S285832","DOIUrl":"https://doi.org/10.2147/PTT.S285832","url":null,"abstract":"<p><p>Psoriasis may manifest as severe hyperkeratotic lesions resembling an oyster shell called ostraceous psoriasis (OP). This type of psoriasis is extremely rare and is often associated with psoriatic arthritis (PA). Cases of OP associated with PA in children have never been reported before. We reported a 9-year-old girl with hyperkeratotic lesions resembling an oyster shell all over the body accompanied with swelling on joints of both fingers, knee joints, and ankle. Histopathological examination supported the diagnosis of OP. The diagnosis of PA was established according to the Classification Criteria for Psoriatic Arthritis (CASPAR). Significant improvements of the skin lesions and joints involved were observed within 44 days after the beginning of treatment with cyclosporine and a combination of high potent topical steroid with emollient. OP associated with PA is uncommonly seen in children. High potent corticosteroid combined with emollient showed good result in skin improvement with low side effects. In addition, cyclosporine can be a good choice of systemic therapy for OP with PA in children.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3e/4d/ptt-10-61.PMC7779316.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38791230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives. 青少年斑块型银屑病的最佳治疗:当前观点。
Pub Date : 2020-11-27 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S222729
Emmanuel Mahé

The skin is at the interface between the body and its environment and is therefore at the center of adolescent concerns during this period of identity formation and increased awareness of body image issues, and stigmatization. Managing an adolescent with psoriasis involves managing the illness and the individual during their transition from being an older child to a young adult. In addition to ensuring that the patient adheres to treatments and is engaged with the therapeutic strategy, dermatologists may also need to manage issues linked to unspoken suffering or conflicts between the adolescent and their parents, who are often present during consultations. The impact of psoriasis on the social interactions, school life and sexuality of the patients, together with the influence of the internet and social networks, also have to be taken into account. In this review, we summarize the epidemiologic, clinical, and therapeutic data available on psoriasis in adolescents, and propose specific management strategies, adapted to the 21st century, for patients in this age group.

皮肤是身体和环境之间的界面,因此是青少年在这个身份形成和对身体形象问题和污名化意识增强的时期关注的中心。管理与牛皮癣青少年包括管理疾病和个人在他们从一个较大的孩子过渡到一个年轻的成年人。除了确保患者坚持治疗并参与治疗策略外,皮肤科医生可能还需要处理与未说出口的痛苦或青少年与父母之间的冲突有关的问题,父母经常在咨询期间出现。牛皮癣对患者的社会交往、学校生活和性行为的影响,以及互联网和社交网络的影响,也必须考虑在内。在这篇综述中,我们总结了青少年牛皮癣的流行病学、临床和治疗方面的资料,并针对这一年龄组的患者提出了适应21世纪的具体管理策略。
{"title":"Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives.","authors":"Emmanuel Mahé","doi":"10.2147/PTT.S222729","DOIUrl":"https://doi.org/10.2147/PTT.S222729","url":null,"abstract":"<p><p>The skin is at the interface between the body and its environment and is therefore at the center of adolescent concerns during this period of identity formation and increased awareness of body image issues, and stigmatization. Managing an adolescent with psoriasis involves managing the illness and the individual during their transition from being an older child to a young adult. In addition to ensuring that the patient adheres to treatments and is engaged with the therapeutic strategy, dermatologists may also need to manage issues linked to unspoken suffering or conflicts between the adolescent and their parents, who are often present during consultations. The impact of psoriasis on the social interactions, school life and sexuality of the patients, together with the influence of the internet and social networks, also have to be taken into account. In this review, we summarize the epidemiologic, clinical, and therapeutic data available on psoriasis in adolescents, and propose specific management strategies, adapted to the 21st century, for patients in this age group.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S222729","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38671510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab. 巨细胞病毒感染:生物治疗的临床挑战?Secukinumab治疗持续免疫球蛋白M抗巨细胞病毒阳性无症状患者1例
Pub Date : 2020-11-27 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S284701
Alessio Gambardella, Gaetano Licata, Giulia Calabrese, Alina De Rosa, Francesca Pagliuca, Roberto Alfano, Giuseppe Argenziano

The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.

使用生物疗法是目前治疗免疫介导性炎症性疾病(IMID)的常见做法。目前,还没有关于巨细胞病毒(CMV)感染或在生物制剂治疗期间再激活的管理指南。此外,对于长时间持续免疫球蛋白(Ig)M抗巨细胞病毒阳性且必须接受生物药物治疗的无症状患者的管理,缺乏指导。我们报告的情况下,病人在这种情况下,谁与生物药物治疗牛皮癣是指。使用secukinumab获得了良好的临床反应,并在6个月的随访中保持。未发生感染性疾病或巨细胞病毒感染再激活。我们对此类病例的处理提出一些可能的指导方针。
{"title":"CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab.","authors":"Alessio Gambardella,&nbsp;Gaetano Licata,&nbsp;Giulia Calabrese,&nbsp;Alina De Rosa,&nbsp;Francesca Pagliuca,&nbsp;Roberto Alfano,&nbsp;Giuseppe Argenziano","doi":"10.2147/PTT.S284701","DOIUrl":"https://doi.org/10.2147/PTT.S284701","url":null,"abstract":"<p><p>The use of biological therapy is now common practice in the treatment of immune-mediated inflammatory diseases (IMID). Currently, there are no guidelines related to the management of cytomegalovirus (CMV) infections or reactivation during therapy with biological agents. Furthermore, there is a lack of guidance on the management of asymptomatic patients with persistent positive immunoglobulin (Ig)M anti-CMV after an extended period and who have to undergo therapy with biological agents. We report the case of a patient in this situation for whom treatment with biological drugs for psoriasis was indicated. A good clinical response was obtained with secukinumab and maintained during 6 months of follow-up. No infectious disease or reactivation of CMV infection occurred. We suggest some possible guidelines for the management of such cases.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S284701","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38680748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter. 控制衰减参数测定银屑病严重程度与非酒精性脂肪性肝病程度的相关性
Pub Date : 2020-10-20 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S272286
Nico Gandha, Larisa Paramitha Wibawa, Tjut Nurul Alam Jacoeb, Andri Sanityoso Sulaiman

Background: A growing body of evidence links psoriasis to several metabolic disorders, but the causal relationship between psoriasis and nonalcoholic fatty liver disease (NAFLD) remains understudied.

Purpose: To measure the correlation between the severity of psoriasis and the degree of NAFLD.

Patients and methods: A cross-sectional study was conducted on adult patients with psoriasis in the Dermatovenereology Outpatient Clinic of Cipto Mangunkusumo Hospital from December 2017 through February 2018. Psoriasis severity (psoriasis area and severity index [PASI] and body surface area [BSA]) was recorded and compared with NAFLD degree measured by controlled attenuation parameter (CAP).

Results: A total of 36 subjects were enrolled with an average age of 49.08 years (±15.52 years). The proportions of mild, moderate, and severe psoriasis were 50%, 27.8%, and 22.2%, respectively. Median of PASI was 6.1 (2-38.4) and BSA was 7.5 (2-93). The proportion of NAFLD was 77.8%. The mean of the CAP score was 250.03±45.64. There was no statistically significant correlation between psoriasis severity based on PASI and CAP score (r = 0.258; p = 0.128). However, if the degree of psoriasis was based on BSA, a significant correlation was found (r = 0.382; p = 0.021). The body mass index (BMI) and abdominal circumference were significantly correlated with CAP score (r = 0.448, p = 0.006 and r = 0.485, p = 0.003, respectively).

Conclusion: Psoriasis extension correlates with NAFLD severity; further studies should assess in detail the effect of therapies on this pathophysiological link.

背景:越来越多的证据表明牛皮癣与几种代谢紊乱有关,但牛皮癣与非酒精性脂肪性肝病(NAFLD)之间的因果关系仍未得到充分研究。目的:探讨银屑病严重程度与NAFLD程度的相关性。患者和方法:对2017年12月至2018年2月在Cipto Mangunkusumo医院皮肤性病门诊就诊的成年牛皮癣患者进行了横断面研究。记录银屑病严重程度(银屑病面积及严重程度指数[PASI]和体表面积[BSA]),并与控制衰减参数(CAP)测定的NAFLD程度进行比较。结果:共纳入36例受试者,平均年龄49.08岁(±15.52岁)。轻度、中度和重度牛皮癣的比例分别为50%、27.8%和22.2%。PASI中位数为6.1 (2-38.4),BSA中位数为7.5(2-93)。NAFLD比例为77.8%。CAP评分平均值为250.03±45.64。基于PASI的银屑病严重程度与CAP评分之间无统计学意义的相关性(r = 0.258;P = 0.128)。然而,如果以牛皮癣的程度为基础,则发现显著相关(r = 0.382;P = 0.021)。体重指数(BMI)和腹围与CAP评分有显著相关(r = 0.448, p = 0.006和r = 0.485, p = 0.003)。结论:银屑病扩展与NAFLD严重程度相关;进一步的研究应详细评估治疗对这种病理生理联系的影响。
{"title":"Correlation Between Psoriasis Severity and Nonalcoholic Fatty Liver Disease Degree Measured Using Controlled Attenuation Parameter.","authors":"Nico Gandha,&nbsp;Larisa Paramitha Wibawa,&nbsp;Tjut Nurul Alam Jacoeb,&nbsp;Andri Sanityoso Sulaiman","doi":"10.2147/PTT.S272286","DOIUrl":"https://doi.org/10.2147/PTT.S272286","url":null,"abstract":"<p><strong>Background: </strong>A growing body of evidence links psoriasis to several metabolic disorders, but the causal relationship between psoriasis and nonalcoholic fatty liver disease (NAFLD) remains understudied.</p><p><strong>Purpose: </strong>To measure the correlation between the severity of psoriasis and the degree of NAFLD.</p><p><strong>Patients and methods: </strong>A cross-sectional study was conducted on adult patients with psoriasis in the Dermatovenereology Outpatient Clinic of Cipto Mangunkusumo Hospital from December 2017 through February 2018. Psoriasis severity (psoriasis area and severity index [PASI] and body surface area [BSA]) was recorded and compared with NAFLD degree measured by controlled attenuation parameter (CAP).</p><p><strong>Results: </strong>A total of 36 subjects were enrolled with an average age of 49.08 years (±15.52 years). The proportions of mild, moderate, and severe psoriasis were 50%, 27.8%, and 22.2%, respectively. Median of PASI was 6.1 (2-38.4) and BSA was 7.5 (2-93). The proportion of NAFLD was 77.8%. The mean of the CAP score was 250.03±45.64. There was no statistically significant correlation between psoriasis severity based on PASI and CAP score (r = 0.258; p = 0.128). However, if the degree of psoriasis was based on BSA, a significant correlation was found (r = 0.382; p = 0.021). The body mass index (BMI) and abdominal circumference were significantly correlated with CAP score (r = 0.448, p = 0.006 and r = 0.485, p = 0.003, respectively).</p><p><strong>Conclusion: </strong>Psoriasis extension correlates with NAFLD severity; further studies should assess in detail the effect of therapies on this pathophysiological link.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S272286","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38539653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
The Skin May Clear But the Arthritis Won't Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy. 皮肤可以清除,但关节炎不会消失:关注银屑病患者在生物治疗的日常实践队列中伴随和新发银屑病关节炎。
Pub Date : 2020-10-05 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S270619
Marloes E van Muijen, Tamara W van Hal, Hans M M Groenewoud, Juul M P A van den Reek, Elke M G J de Jong

Background: Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population.

Objective: We assessed the predictive value of demographic and clinical characteristics for development of PsA in a cohort of patients with moderate-to-severe psoriasis, currently treated with biologics. Furthermore, we reported the incidence of new-onset PsA in this population and described the characteristics of patients that developed PsA during biologic treatment.

Methods: Demographics and treatment characteristics of psoriasis patients currently using biologic therapy were extracted from the BioCAPTURE database (n=427). Poisson regression was used to calculate incidence rates. Multivariable logistic regression was performed to identify factors independently associated with PsA onset. Patient and treatment characteristics of patients that developed PsA during biologic treatment were described.

Results: The incidence of PsA was 1.0 (95% CI 0.8-1.2) per 100 psoriasis-years. Except for a lower risk for PsA in male gender (OR 0.58, 95% CI 0.34-0.98, p-value 0.04), no clinical factors were significantly associated with an altered risk of developing PsA. During biologic therapy, 32 patients (9.4%) newly developed PsA. In this group, 53.8% had PASI<5 at PsA diagnosis. The incidence rate of PsA was 1.6 (95% CI 1.1-2.2) per 100 years on biologic therapy.

Conclusion: Clinical risk factors might be inaccurate to predict PsA onset in patients with moderate-to-severe psoriasis on biologics. Even with low disease activity, psoriasis patients on biologics are still prone to develop PsA.

背景:先前确定的银屑病关节炎(PsA)的危险因素;指甲营养不良和头皮病变在中重度牛皮癣患者中非常普遍。因此,这些变量可能不能作为该人群PsA的预测因子。目的:我们评估人口统计学和临床特征对目前接受生物制剂治疗的中重度牛皮癣患者PsA发展的预测价值。此外,我们报告了该人群中新发PsA的发病率,并描述了在生物治疗期间发生PsA的患者的特征。方法:从BioCAPTURE数据库(n=427)中提取目前使用生物治疗的银屑病患者的人口统计学和治疗特征。用泊松回归计算发病率。进行多变量logistic回归以确定与PsA发病独立相关的因素。描述了在生物治疗过程中发生PsA的患者和治疗特点。结果:PsA的发生率为1.0 (95% CI 0.8-1.2) / 100牛皮癣年。除了男性患PsA的风险较低(OR 0.58, 95% CI 0.34-0.98, p值0.04)外,没有临床因素与PsA发生风险的改变显著相关。生物治疗期间,32例(9.4%)新发PsA。结论:临床危险因素可能无法准确预测使用生物制剂治疗的中重度银屑病患者的PsA发病情况。即使疾病活动度较低,使用生物制剂的牛皮癣患者仍容易发生PsA。
{"title":"The Skin May Clear But the Arthritis Won't Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy.","authors":"Marloes E van Muijen,&nbsp;Tamara W van Hal,&nbsp;Hans M M Groenewoud,&nbsp;Juul M P A van den Reek,&nbsp;Elke M G J de Jong","doi":"10.2147/PTT.S270619","DOIUrl":"https://doi.org/10.2147/PTT.S270619","url":null,"abstract":"<p><strong>Background: </strong>Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore, these variables may not be useful as predictors for PsA in this population.</p><p><strong>Objective: </strong>We assessed the predictive value of demographic and clinical characteristics for development of PsA in a cohort of patients with moderate-to-severe psoriasis, currently treated with biologics. Furthermore, we reported the incidence of new-onset PsA in this population and described the characteristics of patients that developed PsA during biologic treatment.</p><p><strong>Methods: </strong>Demographics and treatment characteristics of psoriasis patients currently using biologic therapy were extracted from the BioCAPTURE database (n=427). Poisson regression was used to calculate incidence rates. Multivariable logistic regression was performed to identify factors independently associated with PsA onset. Patient and treatment characteristics of patients that developed PsA during biologic treatment were described.</p><p><strong>Results: </strong>The incidence of PsA was 1.0 (95% CI 0.8-1.2) per 100 psoriasis-years. Except for a lower risk for PsA in male gender (OR 0.58, 95% CI 0.34-0.98, p-value 0.04), no clinical factors were significantly associated with an altered risk of developing PsA. During biologic therapy, 32 patients (9.4%) newly developed PsA. In this group, 53.8% had PASI<5 at PsA diagnosis. The incidence rate of PsA was 1.6 (95% CI 1.1-2.2) per 100 years on biologic therapy.</p><p><strong>Conclusion: </strong>Clinical risk factors might be inaccurate to predict PsA onset in patients with moderate-to-severe psoriasis on biologics. Even with low disease activity, psoriasis patients on biologics are still prone to develop PsA.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S270619","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38539652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East. 非洲和中东地区斑块型银屑病患者管理临床指南的未满足需求
Pub Date : 2020-08-20 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S264431
Martin Steinhoff, Alfred F Ammoury, Haytham Mohamed Ahmed, Mohamed Fathy Soliman Gamal, Mahira H El Sayed

Purpose: Dermatologists practicing in African and Middle Eastern countries face numerous challenges when managing patients with plaque psoriasis, especially those with disease in a difficult-to-treat anatomic area or those who are a pediatric, geriatric, or pregnant patient. The publication of comprehensive, up-to-date, region-specific clinical guidelines may help to address some of these challenges and improve outcomes. We conducted a literature review to identify recent guidelines and other publications describing patients with plaque psoriasis in Africa and the Middle East.

Patients and methods: An online literature search of the PubMed database was conducted to identify publications reporting clinical guidelines and research studies on plaque psoriasis. The search included all articles published from January 2008 to March 2020 inclusive. The titles and abstracts of all search results were screened by a reader to identify those that described patients in Africa or the Middle East.

Results: A total of 145 publications were identified by the literature search and screened by a reader. There were 10 publications that described patients in Africa or the Middle East: 4 research articles, 3 reviews, 2 guidelines, and 1 case study. The 2010 guidelines from South Africa made recommendations for treating plaque psoriasis of varying severity, although without specific recommendations for difficult-to-treat anatomic areas or pediatric, geriatric, or pregnant patients. The 2014 guideline on biologics from Saudi Arabia included recommendations for the use of these agents in patients with plaque psoriasis, including difficult-to-treat anatomic areas and pediatric patients (TNF inhibitors only), but provided no recommendations for pregnant or geriatric patients.

Conclusion: There is an urgent unmet need for comprehensive clinical guidelines on the management of patients with plaque psoriasis in Africa and the Middle East. Region-specific studies on the epidemiology, burden of disease, and the safety and effectiveness of newer pharmacotherapies are needed to support the development of such guidelines.

目的:在非洲和中东国家执业的皮肤科医生在管理斑块型银屑病患者时面临许多挑战,特别是那些在难以治疗的解剖区域或那些儿童,老年人或孕妇患者的疾病。出版全面的、最新的、特定区域的临床指南可能有助于解决其中的一些挑战并改善结果。我们进行了文献回顾,以确定最近的指南和其他出版物描述斑块银屑病患者在非洲和中东。患者和方法:对PubMed数据库进行在线文献检索,以确定报道斑块性银屑病临床指南和研究的出版物。检索包括2008年1月至2020年3月期间发表的所有文章。所有搜索结果的标题和摘要都由读者筛选,以识别那些描述非洲或中东患者的结果。结果:通过文献检索和读者筛选,共筛选出145篇文献。有10篇出版物描述了非洲或中东的患者:4篇研究文章、3篇综述、2篇指南和1篇案例研究。2010年南非指南对不同严重程度的斑块型银屑病的治疗提出了建议,但没有对难以治疗的解剖部位或儿童、老年人或孕妇患者提出具体建议。沙特阿拉伯2014年的生物制剂指南包括了对斑块型银屑病患者使用这些药物的建议,包括难以治疗的解剖区域和儿科患者(仅限TNF抑制剂),但没有对孕妇或老年患者提供建议。结论:非洲和中东地区迫切需要制定斑块型银屑病患者管理的综合临床指南。需要对流行病学、疾病负担以及新药物治疗的安全性和有效性进行区域特定研究,以支持制定此类指南。
{"title":"The Unmet Need for Clinical Guidelines on the Management of Patients with Plaque Psoriasis in Africa and the Middle East.","authors":"Martin Steinhoff,&nbsp;Alfred F Ammoury,&nbsp;Haytham Mohamed Ahmed,&nbsp;Mohamed Fathy Soliman Gamal,&nbsp;Mahira H El Sayed","doi":"10.2147/PTT.S264431","DOIUrl":"https://doi.org/10.2147/PTT.S264431","url":null,"abstract":"<p><strong>Purpose: </strong>Dermatologists practicing in African and Middle Eastern countries face numerous challenges when managing patients with plaque psoriasis, especially those with disease in a difficult-to-treat anatomic area or those who are a pediatric, geriatric, or pregnant patient. The publication of comprehensive, up-to-date, region-specific clinical guidelines may help to address some of these challenges and improve outcomes. We conducted a literature review to identify recent guidelines and other publications describing patients with plaque psoriasis in Africa and the Middle East.</p><p><strong>Patients and methods: </strong>An online literature search of the PubMed database was conducted to identify publications reporting clinical guidelines and research studies on plaque psoriasis. The search included all articles published from January 2008 to March 2020 inclusive. The titles and abstracts of all search results were screened by a reader to identify those that described patients in Africa or the Middle East.</p><p><strong>Results: </strong>A total of 145 publications were identified by the literature search and screened by a reader. There were 10 publications that described patients in Africa or the Middle East: 4 research articles, 3 reviews, 2 guidelines, and 1 case study. The 2010 guidelines from South Africa made recommendations for treating plaque psoriasis of varying severity, although without specific recommendations for difficult-to-treat anatomic areas or pediatric, geriatric, or pregnant patients. The 2014 guideline on biologics from Saudi Arabia included recommendations for the use of these agents in patients with plaque psoriasis, including difficult-to-treat anatomic areas and pediatric patients (TNF inhibitors only), but provided no recommendations for pregnant or geriatric patients.</p><p><strong>Conclusion: </strong>There is an urgent unmet need for comprehensive clinical guidelines on the management of patients with plaque psoriasis in Africa and the Middle East. Region-specific studies on the epidemiology, burden of disease, and the safety and effectiveness of newer pharmacotherapies are needed to support the development of such guidelines.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S264431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38394542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients. 埃及银屑病患者循环Cell-Free DNA作为炎症标志物
Pub Date : 2020-05-21 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S241750
Haneya A A Anani, Amany M Tawfeik, Soheir S Maklad, Abeer M Kamel, Enas E El-Said, Asmaa S Farag

Background: Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis.

Objective: The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment.

Patients and methods: Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene.

Results: At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment.

Conclusion: The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.

背景:循环中cell-free DNA (CFD)释放引起的细胞病变和凋亡与psoriasis慢性炎症有关。目的:本研究的目的是to确定psoriasis患者血清中的CFD浓度,评估其与银屑病区域严重程度指数(PASI)和其他炎症生物标志物(c -反应蛋白(CRP)和erythrocyte sedimentation rate (ESR))水平定义的疾病严重程度的关系,并监测治疗效果。患者与方法:不同类型成人患者30例psoriasis(寻常型25例;轻度10例,中度15例,红皮病5例;在疾病加重期、开始治疗前(T0)和治疗12周后(T12),对轻度病例进行局部治疗,中度病例进行窄带紫外线B (NB-UVB)治疗,重度病例进行甲氨蝶呤治疗。20名健康对照者也参与了这项研究。采用人β-globin基因引物quantitative real time PCR (qPCR)检测治疗前后血清中CFD的浓度。结果:在T0时,所有患者的ESR (P=0.05)和CFD (P=0.001)水平均显著高于对照组。与轻度/中度疾病(寻常病)相比,在严重疾病(红皮病)中观察到所有参数的显著升高。甲氨蝶呤治疗显著降低了包括CFD在内的所有炎症标志物(P= 0.042),而局部和紫外线照射治疗没有效果。仅在治疗开始前,CFD浓度与PASI (r=0.422, P=0.020)和ESR (r=0.321, P=0.023)呈正相关。结论:循环CFD水平可用于监测psoriasis严重程度。然而,它的水平不能用于治疗,除非在用甲氨蝶呤成功治疗的严重红皮病患者。我们建议验证一个方便和准确的DNA分析直接应用于生物样品,不需要事先DNA提取和扩增。
{"title":"Circulating Cell-Free DNA as Inflammatory Marker in Egyptian Psoriasis Patients.","authors":"Haneya A A Anani,&nbsp;Amany M Tawfeik,&nbsp;Soheir S Maklad,&nbsp;Abeer M Kamel,&nbsp;Enas E El-Said,&nbsp;Asmaa S Farag","doi":"10.2147/PTT.S241750","DOIUrl":"https://doi.org/10.2147/PTT.S241750","url":null,"abstract":"<p><strong>Background: </strong>Cell lesion and apoptosis with release of cell-free DNA (CFD) in circulation are associated with chronic inflammation of psoriasis.</p><p><strong>Objective: </strong>The objective of this study was to determine the CFD concentrations in sera of patients with psoriasis, to assess its relationship with disease severity as defined by Psoriasis Area Severity Index (PASI) and other inflammatory biomarkers (C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)) levels, and to monitor the efficacy of treatment.</p><p><strong>Patients and methods: </strong>Thirty adult patients with different types of psoriasis (25 vulgaris; 10 mild, 15 moderate and 5 erythroderma; severe) were evaluated during the exacerbation phase of the disease, before starting (T0) and after 12 weeks (T12) of treatment with topical therapy for mild cases, narrowband-ultraviolet light B (NB-UVB) for moderate cases and methotrexate for severe cases. Twenty healthy controls were also involved in the study. The concentrations of CFD in sera were measured before and after treatment by quantitative real time PCR (qPCR) using primers of the human β-globin gene.</p><p><strong>Results: </strong>At T0, all patients presented significant higher levels of ESR (P=0.05) and CFD (P=0.001) compared with controls. Highly significant elevations of all parameters were observed in severe disease (erythroderma) compared to mild/moderate disease (vulgaris). Methotrexate treatment induced highly significant reductions in all inflammatory markers including CFD (P= 0.042) while topical and UV irradiation therapies had no effects. CFD concentrations showed positive correlations with both PASI (r=0.422, P=0.020) and ESR (r=0.321, P=0.023) only before the start of treatment.</p><p><strong>Conclusion: </strong>The level of circulating CFD could be used to monitor psoriasis severity. However, its level cannot be stated for the treatment, except in severe erythrodermic patients upon successful treatment with methotrexate. We recommend validation of a convenient and accurate DNA assay applied directly to biological samples which does not require prior DNA extraction and amplification.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S241750","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38109447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKα/β Kinases and Regulates NF-κB /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate. 富马酸二甲酯在银屑病中靶向MSK1、RSK1、2和IKKα/β激酶并调节NF-κB /p65活化:富马酸二甲酯治疗前后对两例重度银屑病患者外周血单个核细胞的影响
Pub Date : 2020-03-31 eCollection Date: 2020-01-01 DOI: 10.2147/PTT.S234151
Borbala Gesser, Mads K Rasmussen, Lars Iversen

Background: Dimethyl fumarate (DMF) has an inhibitory effect on the production of pro-inflammatory proteins from different cells which participate in the immune reaction in psoriatic skin. Most recently it was shown that DMF is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases (RSK1, 2), determined by X-ray crystallography. DMF binds to a specific cysteine residue in RSK2 and in the closely related mitogen and stress-activated kinases 1 (MSK1) which inhibits further downstream activation.

Objectives: The aim of this study was to review the literature on the effects of DMF on activation of MSK1, RSK1, 2 kinases, and downstream transcription factors NF-κB/p65 and IκBα in cells contributing to the pathogenesis of psoriasis. We also hypothesized and studied if treatment with DMF would inhibit the activation of MSK1, RSK1, 2 kinases in peripheral blood mononuclear cells (PBMCs) in psoriatic patients.

Methods: PBMCs were purified from patients with severe psoriasis before and after 90 days of treatment with DMF. Cells were stimulated with anisomycin, IL-1β or EGF for 10 and 20 minutes. The levels of phosphorylation of MSK1, RSK1, 2 or NF-κB/p65, IκBα were analyzed by Western blotting.

Results: Our case study showed that treatment with DMF inhibited the activation of MSK1 and RSK1, 2 kinases in PBMCs in patients. This supports that DMF is the active metabolite in vivo in psoriatic patients during DMF treatment.

Conclusion: Pro-inflammatory proteins are induced through activation of MSK1 and NF-κB/p65 at (S276). The extracellular signal-regulated kinases (ERK1/2) control cell survival by activating both MSK1 and RSK1, 2 kinases. P-RSK1, 2 activates P-κBα and NF-κB/p65 at (S536). The phosphorylation of NF-κB/p65 at (S276) and (S536) controls different T cell and dendritic cell functions. DMF´s inhibitory effect on MSK1 and RSK1, 2 kinase activations reduces multiple immune reactions in psoriatic patients.

背景:富马酸二甲酯(DMF)对银屑病皮肤中参与免疫反应的不同细胞产生促炎蛋白具有抑制作用。最近的研究表明,DMF是p90核糖体S6激酶的变构共价抑制剂(rsk1,2),由x射线晶体学测定。DMF结合RSK2和密切相关的有丝分裂原和应激激活激酶1 (MSK1)中的特定半胱氨酸残基,抑制进一步的下游激活。目的:综述DMF对银屑病发病细胞中MSK1、RSK1、2激酶及下游转录因子NF-κB/p65和i -κB α活化的影响。我们还假设并研究了DMF治疗是否会抑制银屑病患者外周血单个核细胞(PBMCs)中MSK1, rsk1,2激酶的激活。方法:从重度银屑病患者DMF治疗前和治疗后90天纯化PBMCs。用大霉素、IL-1β或EGF刺激细胞10和20分钟。Western blotting分析MSK1、RSK1、2或NF-κB/p65、i -κB α磷酸化水平。结果:我们的病例研究表明,用DMF治疗可以抑制患者PBMCs中MSK1和rsk1,2激酶的激活。这支持DMF是银屑病患者在DMF治疗期间体内的活性代谢物。结论:促炎蛋白是通过MSK1和NF-κB/p65在(S276)处的活化而诱导的。细胞外信号调节激酶(ERK1/2)通过激活MSK1和rsk1,2激酶来控制细胞存活。P- rsk1,2激活P-κBα和NF-κB/p65 (S536)。NF-κB/p65在(S276)和(S536)位点的磷酸化控制不同的T细胞和树突状细胞功能。DMF对银屑病患者MSK1和rsk1,2激酶激活的抑制作用可减少多种免疫反应。
{"title":"Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKα/β Kinases and Regulates NF-κB /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate.","authors":"Borbala Gesser,&nbsp;Mads K Rasmussen,&nbsp;Lars Iversen","doi":"10.2147/PTT.S234151","DOIUrl":"https://doi.org/10.2147/PTT.S234151","url":null,"abstract":"<p><strong>Background: </strong>Dimethyl fumarate (DMF) has an inhibitory effect on the production of pro-inflammatory proteins from different cells which participate in the immune reaction in psoriatic skin. Most recently it was shown that DMF is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases (RSK1, 2), determined by X-ray crystallography. DMF binds to a specific cysteine residue in RSK2 and in the closely related mitogen and stress-activated kinases 1 (MSK1) which inhibits further downstream activation.</p><p><strong>Objectives: </strong>The aim of this study was to review the literature on the effects of DMF on activation of MSK1, RSK1, 2 kinases, and downstream transcription factors NF-κB/p65 and IκBα in cells contributing to the pathogenesis of psoriasis. We also hypothesized and studied if treatment with DMF would inhibit the activation of MSK1, RSK1, 2 kinases in peripheral blood mononuclear cells (PBMCs) in psoriatic patients.</p><p><strong>Methods: </strong>PBMCs were purified from patients with severe psoriasis before and after 90 days of treatment with DMF. Cells were stimulated with anisomycin, IL-1β or EGF for 10 and 20 minutes. The levels of phosphorylation of MSK1, RSK1, 2 or NF-κB/p65, IκBα were analyzed by Western blotting.</p><p><strong>Results: </strong>Our case study showed that treatment with DMF inhibited the activation of MSK1 and RSK1, 2 kinases in PBMCs in patients. This supports that DMF is the active metabolite in vivo in psoriatic patients during DMF treatment.</p><p><strong>Conclusion: </strong>Pro-inflammatory proteins are induced through activation of MSK1 and NF-κB/p65 at (S276). The extracellular signal-regulated kinases (ERK1/2) control cell survival by activating both MSK1 and RSK1, 2 kinases. P-RSK1, 2 activates P-κBα and NF-κB/p65 at (S536). The phosphorylation of NF-κB/p65 at (S276) and (S536) controls different T cell and dendritic cell functions. DMF´s inhibitory effect on MSK1 and RSK1, 2 kinase activations reduces multiple immune reactions in psoriatic patients.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S234151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37851812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. 托法替尼治疗活动性银屑病关节炎:患者选择和前景。
Pub Date : 2019-08-28 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S161453
Karen Ly, Kristen M Beck, Mary P Smith, Ana-Maria Orbai, Wilson Liao

Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib.

托法替尼是一种口服Janus激酶抑制剂,被批准用于治疗银屑病关节炎(PsA)。它为那些对其他治疗疾病的抗风湿药物(DMARD)反应和耐受性不足的患者提供了一种替代选择。它已经证明了与生物制剂相当的疗效,在治疗耐药性疾病方面是有效的,并且据报道可以改善附着点炎、指甲炎和放射学进展。托法替尼还与严重感染、恶性肿瘤和实验室异常的风险增加有关。目前有大量治疗银屑病关节炎的药物,在治疗方法中进行选择可能具有挑战性。由于这种广泛的选择,彻底评估银屑病的表型、患者偏好、疾病表现和合并症至关重要。这篇综述阐述了选择托法替尼治疗银屑病患者的关键考虑因素。
{"title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.","authors":"Karen Ly,&nbsp;Kristen M Beck,&nbsp;Mary P Smith,&nbsp;Ana-Maria Orbai,&nbsp;Wilson Liao","doi":"10.2147/PTT.S161453","DOIUrl":"https://doi.org/10.2147/PTT.S161453","url":null,"abstract":"<p><p>Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs). It has demonstrated comparable efficacy to biologics, is effective in the management of treatment resistant disease, and is reported to improve enthesitis, dactylitis, and radiographic progression. Tofacitinib is also associated with an increased risk of serious infections, malignancy, and laboratory abnormalities. There is currently a large armamentarium of therapies for psoriatic arthritis, and choosing among treatments can be challenging. Due to this wide selection, a thorough assessment of psoriatic disease phenotype, patient preference, disease presentation, and comorbidities is critical. This review addresses key considerations in patient selection for the treatment of PsA with tofacitinib.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S161453","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41222940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential. 治疗中重度斑块型银屑病和银屑病关节炎的新治疗方案:评估比美珠单抗及其治疗潜力
Pub Date : 2019-05-24 eCollection Date: 2019-01-01 DOI: 10.2147/PTT.S179283
Andrea Chiricozzi, Clara De Simone, Barbara Fossati, Ketty Peris

Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.

斑块型银屑病(PsO)是一种慢性炎症性皮肤病,可能与包括关节炎在内的几种合并症有关。对牛皮癣发病机制的认识不断增加,导致了新的靶向治疗干预措施的确定。其中,抗il - 17a和抗il - 17f抗体目前正在研究用于治疗PsO和/或银屑病关节炎(PsA)。Bimekizumab是其中一种药物,能够同时中和IL-17A和IL-17F细胞因子。在这篇综述中,我们包括了与这种非常有前途的药物相关的临床前和临床数据,该药物显示出与其他双特异性药物不同的特殊分子结构。
{"title":"Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.","authors":"Andrea Chiricozzi,&nbsp;Clara De Simone,&nbsp;Barbara Fossati,&nbsp;Ketty Peris","doi":"10.2147/PTT.S179283","DOIUrl":"https://doi.org/10.2147/PTT.S179283","url":null,"abstract":"<p><p>Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/PTT.S179283","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37341565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
期刊
Psoriasis (Auckland, N.Z.)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1